化疗引起的贫血市场 - 全球产业规模、份额、趋势、机会和预测，按疾病类型、治疗类型、药物类型、最终用户、地区和竞争细分，2020-2030 年预测

2024 年全球化疗引起的贫血 (CIA) 市场价值为 28.6 亿美元，预计到 2030 年将达到 43.1 亿美元，预测期内的年复合成长率(CAGR) 为 7.02%。化疗引起的贫血市场已成为肿瘤学领域的重点，化疗是癌症患者的主要治疗方法。随着化疗的应用不断增加，化疗引起的贫血的盛行率也随之增加。这种疾病不仅影响癌症患者的生活质量，也为製药公司和医疗保健提供者带来了巨大的商机。

化疗引起的贫血是化疗的常见副作用，是由于化疗药物损害骨髓产生红血球的能力，从而降低血液中的血红蛋白水平而发生的。这种情况会导致疲劳、虚弱、呼吸急促以及对进一步癌症治疗的耐受性降低等症状。因此，CIA 的管理已成为癌症治疗的关键方面，从而导致对有效治疗的需求增加。

CIA 影响着广泛的癌症患者，美国癌症协会报告称，30-90% 接受化疗的癌症患者会出现不同程度的贫血。 CIA 的治疗方法包括红血球生成刺激剂 (ESA)、铁补充剂、输血和新兴疗法。 ESA，包括促红血球生成素刺激剂和达贝泊汀α，一直被广泛用于治疗这种疾病，但安全问题和监管变化影响了它们的使用。 CIA 市场的关键参与者包括安进、强生和罗氏等大型製药公司，这些公司正在开发和行销针对这种疾病的治疗方法。

CIA 市场充满活力，既充满挑战也充满机会。监管问题和报销问题构成了重大障碍，但持续的研究、以患者为中心的护理、行业合作和市场扩张带来了光明的未来。随着医疗保健产业继续优先考虑癌症患者的健康，CIA 管理的进步对于改善化疗患者的生活品质至关重要。製药公司和医疗保健提供者必须保持敏捷和创新，以满足不断增长的患者群体的需求。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：顾客之声

第 5 章：全球化疗引起的贫血市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依疾病类型（轻度贫血、中度贫血、重度贫血）
  • 依治疗类型（红血球输注、红血球生成刺激剂 (ESA)、铁补充剂）
  • 依药物类型（Epogen 注射、Procrit 注射、Androxy 口服液、Aranesp 注射、Epoetin Alfa 注射、其他）
  • 按最终使用者（医院和诊所、门诊护理中心、其他）
  • 按地区
  • 按公司分类（2024）
• 市场地图

第 6 章：北美化疗引起的贫血市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 加拿大
  • 墨西哥

第 7 章：欧洲化疗引起的贫血市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 英国
  • 义大利
  • 法国
  • 西班牙

第 8 章：亚太地区化疗引起的贫血市场展望

• 市场规模和预测
• 市场占有率和预测
• 亚太地区：国家分析
  • 印度
  • 日本
  • 韩国
  • 澳洲

第 9 章：南美洲化疗引起的贫血市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 10 章：中东和非洲化疗引起的贫血市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：市场动态

• 驱动程式
• 挑战

第 12 章：市场趋势与发展

• 合併与收购（如有）
• 产品发布（如果有）
• 最新动态

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• Panacea Biotec Limited
• SBI Pharmaceuticals Co., Ltd
• Sumitomo Dainippon Pharma Co., Ltd.
• PharmaEssentia Corp.
• PhytoHealth Corp
• UBI Pharma Inc.
• Amgen Inc.
• Astellas Pharma Inc.

第 15 章：策略建议

第16章 调査会社について・免责事项

The Global Chemotherapy-Induced Anemia (CIA) Market was valued at USD 2.86 billion in 2024 and is projected to reach USD 4.31 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.02% during the forecast period. The market for chemotherapy-induced anemia has become a significant focus within the oncology sector, with chemotherapy being a primary treatment for cancer patients. As chemotherapy use continues to rise, the prevalence of chemotherapy-induced anemia has concurrently increased. This condition not only impacts cancer patients' quality of life but also presents substantial business opportunities for pharmaceutical companies and healthcare providers.

Chemotherapy-induced anemia is a common side effect of chemotherapy, occurring when chemotherapy drugs impair the bone marrow's ability to produce red blood cells, thereby reducing hemoglobin levels in the blood. This condition can result in symptoms such as fatigue, weakness, shortness of breath, and a reduced tolerance for further cancer treatments. As a result, the management of CIA has become a key aspect of cancer care, leading to increased demand for effective treatments.

CIA affects a wide range of cancer patients, with the American Cancer Society reporting that 30-90% of cancer patients undergoing chemotherapy experience varying degrees of anemia. Treatments for CIA include erythropoiesis-stimulating agents (ESAs), iron supplements, blood transfusions, and emerging therapies. ESAs, including erythropoietin-stimulating agents and darbepoetin alfa, have been commonly used to manage the condition, although safety concerns and regulatory changes have impacted their usage. Key players in the CIA market include major pharmaceutical companies such as Amgen, Johnson & Johnson, and Roche, which are developing and marketing treatments for this condition.

The CIA market is dynamic, presenting both challenges and opportunities. Regulatory concerns and reimbursement issues pose significant hurdles, but ongoing research, patient-centered care, industry collaboration, and market expansion offer a promising future. As the healthcare industry continues to prioritize cancer patient well-being, advancements in CIA management will be crucial to improving the quality of life for those undergoing chemotherapy. Pharmaceutical companies and healthcare providers must remain agile and innovative to meet the needs of this growing patient population.

Key Market Drivers

Increasing Incidence of Cancer: The global incidence of cancer is a significant driver of the chemotherapy-induced anemia market. As cancer cases continue to rise, so does the demand for effective treatments, including chemotherapy. Despite its effectiveness, chemotherapy is associated with side effects such as CIA, which is gaining increased attention. The rising cancer incidence is prompting research, innovation, and the development of therapies to manage this condition.

According to the World Cancer Research Fund, there were 19,976,499 cancer cases worldwide in 2022, including non-melanoma skin cancer. Excluding non-melanoma skin cancer, the number of cases was 18,741,966, with nearly equal distribution between men (9,566,825 cases) and women (9,175,141 cases).

Key Market Challenges

Regulatory Barriers: Regulatory hurdles pose significant challenges for companies in the CIA market. Navigating the complex regulatory environment requires substantial resources and time. Regulatory agencies, including the FDA and EMA, require extensive preclinical and clinical data to evaluate the safety and efficacy of new therapies. This process is often lengthy and costly, delaying time to market and increasing financial strain for companies. Regulatory requirements also vary across regions, further complicating international market expansion. Smaller firms, in particular, face challenges competing with larger, more established companies with greater resources and experience in managing regulatory processes.

Key Market Trends

Rising Awareness and Early Diagnosis of Chemotherapy-Induced Anemia: Increasing awareness and early diagnosis of CIA is a major driver of the global market. As cancer incidence grows and treatment regimens become more complex, there is greater recognition of the impact of chemotherapy-induced anemia on patients' quality of life. Previously underdiagnosed or underappreciated, CIA is now receiving more attention from healthcare professionals, leading to an increased demand for treatment options.

Key Market Players

• Dr. Reddy's Laboratories Ltd.
• Pfizer Inc.
• Panacea Biotec Limited
• SBI Pharmaceuticals Co., Ltd.
• Sumitomo Dainippon Pharma Co., Ltd.
• PharmaEssentia Corp.
• PhytoHealth Corp
• UBI Pharma Inc.
• Amgen Inc.
• Astellas Pharma Inc.

Report Scope

This report segments the Global Chemotherapy-Induced Anemia Market as follows:

By Disease Type:

• Mild Anemia
• Moderate Anemia
• Severe Anemia

By Treatment Type:

• RBC Transfusions
• Erythropoiesis-Stimulating Agents (ESAs)
• Iron Supplementation

By Drug Type:

• Epogen Injection
• Procrit Injection
• Androxy Oral
• Aranesp Injection
• Epoetin Alfa Injection
• Others

By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

By Region:

• North America: United States, Canada, Mexico
• Europe: France, United Kingdom, Italy, Germany, Spain
• Asia-Pacific: China, India, Japan, Australia, South Korea
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape

This section provides a detailed analysis of the major companies operating in the Chemotherapy-Induced Anemia Market.

Available Customizations

The Global Chemotherapy-Induced Anemia market report offers the following customizations tailored to the needs of specific companies:

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Chemotherapy-Induced Anemia Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Disease Type (Mild Anemia, Moderate Anemia, Severe Anemia)
  • 5.2.2. By Treatment Type (RBC Transfusions, Erythropoiesis-stimulating agents (ESAs), Iron Supplementation)
  • 5.2.3. By Drug Type (Epogen Injection, Procrit Injection, Androxy Oral, Aranesp injection, Epoetin Alfa Injection, Others)
  • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Chemotherapy-Induced Anemia Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Disease Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Drug Type
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Chemotherapy-Induced Anemia Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Disease Type
      • 6.3.1.2.2. By Treatment Type
      • 6.3.1.2.3. By Drug Type
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Chemotherapy-Induced Anemia Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Disease Type
      • 6.3.2.2.2. By Treatment Type
      • 6.3.2.2.3. By Drug Type
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Chemotherapy-Induced Anemia Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Disease Type
      • 6.3.3.2.2. By Treatment Type
      • 6.3.3.2.3. By Drug Type
      • 6.3.3.2.4. By End User

7. Europe Chemotherapy-Induced Anemia Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Disease Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Drug Type
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Chemotherapy-Induced Anemia Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Disease Type
      • 7.3.1.2.2. By Treatment Type
      • 7.3.1.2.3. By Drug Type
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Chemotherapy-Induced Anemia Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Disease Type
      • 7.3.2.2.2. By Treatment Type
      • 7.3.2.2.3. By Drug Type
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Chemotherapy-Induced Anemia Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Disease Type
      • 7.3.3.2.2. By Treatment Type
      • 7.3.3.2.3. By Drug Type
      • 7.3.3.2.4. By End User
  • 7.3.4. France Chemotherapy-Induced Anemia Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Disease Type
      • 7.3.4.2.2. By Treatment Type
      • 7.3.4.2.3. By Drug Type
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Chemotherapy-Induced Anemia Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Disease Type
      • 7.3.5.2.2. By Treatment Type
      • 7.3.5.2.3. By Drug Type
      • 7.3.5.2.4. By End User

8. Asia-Pacific Chemotherapy-Induced Anemia Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Disease Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Drug Type
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Chemotherapy-Induced Anemia Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Disease Type
      • 8.3.1.2.2. By Treatment Type
      • 8.3.1.2.3. By Drug Type
      • 8.3.1.2.4. By End User
  • 8.3.2. India Chemotherapy-Induced Anemia Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Disease Type
      • 8.3.2.2.2. By Treatment Type
      • 8.3.2.2.3. By Drug Type
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Chemotherapy-Induced Anemia Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Disease Type
      • 8.3.3.2.2. By Treatment Type
      • 8.3.3.2.3. By Drug Type
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Chemotherapy-Induced Anemia Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Disease Type
      • 8.3.4.2.2. By Treatment Type
      • 8.3.4.2.3. By Drug Type
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Chemotherapy-Induced Anemia Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Disease Type
      • 8.3.5.2.2. By Treatment Type
      • 8.3.5.2.3. By Drug Type
      • 8.3.5.2.4. By End User

9. South America Chemotherapy-Induced Anemia Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Disease Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Drug Type
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Chemotherapy-Induced Anemia Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Disease Type
      • 9.3.1.2.2. By Treatment Type
      • 9.3.1.2.3. By Drug Type
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Chemotherapy-Induced Anemia Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Disease Type
      • 9.3.2.2.2. By Treatment Type
      • 9.3.2.2.3. By Drug Type
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Chemotherapy-Induced Anemia Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Disease Type
      • 9.3.3.2.2. By Treatment Type
      • 9.3.3.2.3. By Drug Type
      • 9.3.3.2.4. By End User

10. Middle East and Africa Chemotherapy-Induced Anemia Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Disease Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Drug Type
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Chemotherapy-Induced Anemia Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Disease Type
      • 10.3.1.2.2. By Treatment Type
      • 10.3.1.2.3. By Drug Type
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Chemotherapy-Induced Anemia Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Disease Type
      • 10.3.2.2.2. By Treatment Type
      • 10.3.2.2.3. By Drug Type
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Chemotherapy-Induced Anemia Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Disease Type
      • 10.3.3.2.2. By Treatment Type
      • 10.3.3.2.3. By Drug Type
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Dr. Reddy's Laboratories Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Panacea Biotec Limited
• 14.4. SBI Pharmaceuticals Co., Ltd
• 14.5. Sumitomo Dainippon Pharma Co., Ltd.
• 14.6. PharmaEssentia Corp.
• 14.7. PhytoHealth Corp
• 14.8. UBI Pharma Inc.
• 14.9. Amgen Inc.
• 14.10. Astellas Pharma Inc.

15. Strategic Recommendations

16. About Us & Disclaimer